CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET
|
CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
04. November 2024 07:00 ET
|
CytoSorbents
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET
|
CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
01. Oktober 2024 07:00 ET
|
CytoSorbents
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02. Mai 2024 07:00 ET
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28. Dezember 2023 07:00 ET
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices
21. Februar 2023 01:00 ET
|
Xeltis
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...
Corline Biomedical AB: Tecknar samarbetsavtal för CHS™-coatning av bypassgraft med ambition att starta kliniska studier 2023
17. Februar 2023 12:00 ET
|
Corline Biomedical AB
Corline har tecknat ett utvecklings- och samarbetsavtal med en europeisk leverantör av kärlgrafter för bypassoperationer som används vid kirurgi för patienter med hjärtinfarkt. Avtalet reglerar...